NPS Pharmaceuticals, Inc. (NPSP)
-NasdaqGM 14.53 
0.42(2.98%) 4:00PM EDT
| Prev Close: | 14.11 |
|---|
| Open: | 14.01 |
|---|
| Bid: | 14.53 x 500 |
|---|
| Ask: | 16.03 x 1000 |
|---|
| 1y Target Est: | 18.67 |
|---|
| Beta: | 0.63 |
|---|
| Next Earnings Date: | 29-Jul-13 |
|---|
| Day's Range: | 13.79 - 14.89 |
|---|
| 52wk Range: | 6.62 - 14.89 |
|---|
| Volume: | 2,153,953 |
|---|
| Avg Vol (3m): | 1,959,210 |
|---|
| Market Cap: | 1.37B |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.19 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- InPlay: NPS Pharm prices 6 mln share public offering of common stock at $14.53 per shareBriefing.com(Tue 5:58PM EDT)
- NPS Pharmaceuticals Prices Public Offering of Common StockBusiness Wire(Tue 5:57PM EDT)
- NPS Pharmaceuticals Announces Proposed Public Offering of 6,000,000 Shares of its Common StockBusiness Wire(Mon, May 20)
- NPS Pharmaceuticals President and CEO Dr. Francois Nader Recognized as Regional Finalist for Ernst & Young Entrepreneur of the Year® 2013Business Wire(Thu, May 16)
- NPS PHARMACEUTICALS INC FinancialsEDGAR Online Financials(Wed, May 15)
- NPS Pharmaceuticals Recognized by National Organization for Rare Disorders for Gattex® as an Innovative Treatment for Patients with Short Bowel SyndromeBusiness Wire(Wed, May 15)
- NPS Pharmaceuticals Inc Stock Upgraded (NPSP)at TheStreet(Tue, May 14)
- 3 Healthcare Stock Winners and 1 Loser After Earnings Are Digestedat Wall St. Cheat Sheet(Sun, May 12)
- NPS Pharma rises on early sales of bowel drugAP(Thu, May 9)
- Why NPS Pharmaceuticals Is Up After Earningsat Motley Fool(Thu, May 9)
- NPS Pharmaceuticals' CEO Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Thu, May 9)
- NPS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a VotEDGAR Online(Thu, May 9)
- NPS Pharmaceuticals Earnings Call scheduled for 8:30 am ET todayCCBN(Thu, May 9)
- NPS Pharmaceuticals Reports First Quarter 2013 Financial ResultsBusiness Wire(Thu, May 9)
- Q1 2013 NPS Pharmaceuticals Earnings Release - Before Market OpenCCBN(Thu, May 9)
Key Statistics
| Forward P/E (1 yr): | 37.26 |
|---|
| P/S (ttm): | 12.28 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.19 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.07 |
|---|
| Mean Recommendation*: | 1.5 |
|---|
| PEG Ratio (5 yr expected): | -2.24 |
|---|
Business Summary
NPS Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapeutic products in the United States. Its lead product is Gattex for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on pa...
View More